A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-10 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
In a 3 January 2026 editorial, The New York Times editorial board condemned the attack as "dangerous and illegal", describing it as an act of "latter-day imperialism" which lacked "any semblance of international legitimacy, valid legal authority or domestic endorsement". Comparing the attack to interventions in Libya, the war in Afghanistan, and US involvement in Nicaragua, it warned of the "potential for chaos in Venezuela", including violence from paramilitary groups such as the Venezuelan colectivos or the Colombian National Liberation Army (ELN), which operates in western Venezuela. The AFL-CIO condemned the attack, calling it unconstitutional. Many analysts liken the operation in Venezuela to prior operations, such as Operation Nifty Package which led to the capture of Panamanian military leader, Manuel Noriega, as well as Operation Red Dawn, which led to the capture of former Iraqi president, Saddam Hussein.
In Winter 1996, Kenyon's co-authored paper, "The RNA World: A Critique," appeared in Origins and Design, a now defunct creationist journal where he was on the Editorial Advisory Board. He continued publicly arguing in favor of creationism, notably at the 1998 International Conference on Creationism. Currently, Kenyon is a speaker, writer, and board member for the Kolbe Center, a Catholic YEC group. In 2008, Kenyon endorsed a young Earth creationist book promoted by the Center.
=== Flours === Functional flours are produced from specific cereal variety (wheat, maize, rice or other) conjugated to specific heat treatment able to increase stability, consistency and general functionalities. These functional flours are resistant to industrial stresses such as acidic pH, sterilisation, freeze conditions, and can help food industries to formulate with natural ingredients. For the final consumer, these ingredients are more accepted because they are shown as "flour" in the ingredient list. Flour is often used for thickening gravies, gumbos, and stews. The most basic type of thickening agent, flour blended with water to make a paste, is called whitewash. It must be cooked in thoroughly to avoid the taste of uncooked flour. Roux, a mixture of flour and fat (usually butter) cooked into a paste, is used for gravies, sauces and stews. Cereal grains (oatmeal, couscous, farina, etc.) are used to thicken soups. Yogurt is popular in Eastern Europe and Middle East for thickening soups. Soups can also be thickened by adding grated starchy vegetables before cooking, though these will add their own flavour. Tomato puree also adds thickness as well as flavour. Egg yolks are a traditional sauce thickener in professional cooking; they have rich flavor and offer a velvety smooth texture but achieve the desired thickening effect only in a narrow temperature range. Overheating easily ruins such a sauce, which can make egg yolk difficult to use as a thickener for amateur cooks. Other thickeners used by cooks are nuts (including rehan) or glaces made of meat or fish.
Sources: en.wikipedia.org
== Career == Baldwin began acting professionally as a teenager, landing the role of Ricky Linderman in the Chicago-set film My Bodyguard (1980). That same year he appeared in Robert Redford's Academy Award-winning drama Ordinary People as Kevin Stillman. In the early 1980s he continued with supporting roles in films including D.C. Cab (1983) and Reckless (1984). By the late 1980s he had moved into higher-profile studio productions, including Stanley Kubrick's Vietnam War film Full Metal Jacket (1987), in which he played the Marine nicknamed "Animal Mother," and the crime thriller Next of Kin (1989). In the 1990s he appeared in a run of mainstream features including Predator 2 (1990), the western biopic Wyatt Earp (1994) portraying Tom McLaury, and the science-fiction blockbuster Independence Day (1996). He later played Captain Wilkins in Roland Emmerich's Revolutionary War film The Patriot (2000). On television, Baldwin became a regular cast member of Joss Whedon's science-fiction series Firefly (2002–2003) as the mercenary Jayne Cobb, and reprised the role in the continuation film Serenity (2005). From 2007 to 2012 he played the National Security Agency agent John Casey on NBC's action-comedy series Chuck. His other television work includes a regular role on ABC's Day Break (2006–2007) and a lead role on the 1996–1997 drama series The Cape as Col. Jack Riles. He made a brief on-screen return to the schoolyard premise of My Bodyguard with a cameo in the comedy Drillbit Taylor (2008), noted as an explicit nod to his earlier film.
A US- and UK-backed coup d'état in 1953 deposed the democratically-elected Iranian prime minister Mohammad Mosaddegh due to his nationalization of the oil industry, strengthening the rule of Shah Mohammad Reza Pahlavi. Israel maintained ties with Iran as part of its alliance of the periphery strategy. Resentment of the Shah's autocratic rule led to the 1979 revolution in which Pahlavi was overthrown and replaced by an Islamic republic. Iran severed diplomatic ties with the US and Israel and held the American embassy staff hostage, releasing them after signing the Algiers Accords (1981), in which, among other things, the US agreed not to intervene in Iranian affairs anymore. During the Iran–Iraq War, the US supported Iraq. In 1988, a US warship struck an Iranian mine, and the US responded by attacking Iran's navy. A few months later, the US mistakenly shot down a civilian Iranian flight. Iran started a ballistic missile program to deter Iraqi missile attacks on Iranian cities during the 1980–88 Iran–Iraq War and to compensate for its lack of a modern air force due to sanctions. Starting in 1985, Iran began engaging in proxy conflicts throughout the Middle East. These proxy groups became part of the informal 'Axis of Resistance' committed primarily to countering American, Israeli, Saudi, Emirati, and sometimes Turkish influence in the region. In 2002, Iran's covert nuclear program was first revealed, and Iran denied seeking a weapon. In 2003, Iran's AMAD Project was suspended following Supreme Leader Ali Khamenei's fatwa against nuclear weapons.
Patent leather is leather that has been given a high-gloss finish by the addition of a coating. Dating to the late 1700s, it became widely popular after inventor Seth Boyden developed the first mass-production process, using a linseed-oil-based lacquer, in 1818. Modern versions are usually a form of bicast leather. Suede is made from the underside of a split to create a soft, napped finish. It is often made from younger or smaller animals, as the skins of adults often result in a coarse, shaggy nap. Bonded leather, also called reconstituted leather, is a material that uses leather scraps that are shredded and bonded together with polyurethane or latex onto a fiber mesh. The amount of leather fibers in the mix varies from 10% to 90%, affecting the properties of the product. The term "genuine leather" does not describe a specific grade. The term often indicates split leather that has been extensively processed, and some sources describe it as synonymous with bicast leather, or made from multiple splits glued together and coated. In some countries, when it is the description on a product label the term means nothing more than "contains leather"; depending on jurisdiction, regulations limit the term's use in product labelling.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.